Abstract Details

Title An Update on STEADY-PD III: A Phase 3 Study of Isradipine as a Disease Modifying Agent in Patients with Early Parkinson’s Disease

Topic Movement Disorders

Presentation(s) (-)

Poster/Presentation
Number 341

Objective

Background

Design/Methods

Results

Conclusions

Authors/Disclosures
Tanya Simuni, MD, FAAN (Northwestern University Feinberg School of Medicien) PRESENTER	Dr. Simuni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for cadia, AcureX, Adamas, AskBio, Amneal, Blue Rock Therapeutics, Caraway Therapeutics, Critical Path for Parkinson's Consortium (CPP), Denali, Michael J Fox Foundation, Neuroderm, Sanofi, Sinopia, Roche, Takeda and Vanqua Bio. Dr. Simuni has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for of Koneksa, Neuroderm, Sanofi, UCB, AcureX, Adamas, AskBio, Biohaven, Denali, GAIN, Neuron23 and Roche. Dr. Simuni has received research support from Amneal, Biogen, Neuroderm, Prevail, Roche, and UCB and an investigator for NINDS, MJFF, Parkinson's Foundation.
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
	No disclosure on file
Kevin M. Biglan, MD (Eli Lilly)	Dr. Biglan has received personal compensation for serving as an employee of Eli Lilly. Dr. Biglan has received stock or an ownership interest from Eli Lilly.

��ɫ��